FDA Inspection 1039234 — Hyo Jong Kim
The FDA completed an inspection of Hyo Jong Kim on Oct 26, 2017 in Seoul. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 26, 2017
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Seoul (Korea (the Republic of))
Additional details
Clinical Investigator (CI)